Factor 8 SHL denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for factor 8 shl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Factor VIII (SHL) as Non-Formulary

Blue Cross Blue Shield's non-formulary denial means the specific extended half-life (SHL) Factor VIII product your hematologist prescribed is not included on your plan's drug formulary — or is placed at a tier that triggers a formulary exception requirement.

Formulary denials are appealable through a formulary exception process, separate from (but sometimes combined with) a standard medical-necessity appeal. The standard for a formulary exception is typically that all covered alternatives are clinically inappropriate for your specific situation.

## Federal Appeal Rights

• ACA §2719: non-formulary denials are subject to internal and independent external review for most non-grandfathered plans.
• ERISA §503: employer-plan members have full-and-fair review rights.
• You generally have approximately four months from the denial to request external review if the internal exception request is denied.
• Expedited review: available when your physician certifies that delay poses a serious health risk.

## Concrete Appeal Timeline

1. Request a formulary exception (sometimes called a coverage exception or medical exception) — this is often a separate form from a standard appeal. 2. Simultaneously file a standard medical-necessity appeal if one is available. 3. If both are denied, escalate to external review.

## Documentation to Gather

• List of formulary alternatives: obtain BCBS's current formulary list of covered Factor VIII products. Your hematologist must address each one.
• Clinical contraindication or inadequacy documentation: for each covered formulary alternative, chart documentation or a prescriber statement explaining why it is clinically inappropriate — for example, inadequate bleed control on a standard half-life product, treatment burden, or documented adverse outcomes.
• Pharmacokinetic rationale: if applicable, individual PK profiling results that justify SHL over standard half-life products.
• Diagnosis and severity documentation: complete hemophilia A records, FVIII activity, inhibitor status, and annualized bleed history.
• Prescriber medical-necessity letter for formulary exception: explicitly states that each formulary alternative is contraindicated, ineffective, or otherwise clinically inappropriate for this patient — this is the core of a formulary exception request.

## Criteria-Mapping Structure

Formulary exception criteria typically require showing that covered alternatives are not medically appropriate. Build a side-by-side table:

| Formulary-Listed Alternative | Reason Clinically Inappropriate for This Patient | |---|---| | [Standard half-life Factor VIII Product A] | [Documented outcome from chart — e.g., breakthrough bleeds on prior trial, PK data showing inadequate trough] | | [Standard half-life Factor VIII Product B] | [Clinical rationale per hematologist's letter] |

Verify the exact formulary exception criteria in your BCBS Evidence of Coverage document and in BCBS's published medical policy for Factor VIII products. Also confirm all coverage details against the FDA-approved prescribing information for the prescribed SHL product. Formulary tiers and exception standards vary by plan year and product; always use the documents current at the time of your denial.